ACG Education Universe - An online learning resource from the American College of Gastroenterology

 

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments.

The vast majority of the material presented in the ACG Educational Universe has previously been presented in lecture or other learning format, and author disclosure information reflects the content and format for disclosure provided by the presenter as of the date that his/her material was presented and captured electronically, and in compliance with ACG policies and ACCME requirements in effect as of that date of presentation. Author and planner conflicts were identified and resolved in accordance with ACG’s Policies and Procedures on Identifying and Resolving Conflicts of Interest.

Unapproved 'Off-Label' Usage Policy

If any unapproved or off-label use of a product is to be referenced in a CME program presentation, the faculty member shall be required to disclose that the product is either investigational or it is not labeled for the usage being discussed.

Universe Editorial Board

It is the role of the Editors to assist with the strategic direction of the ACG Education Universe, assist with decisions relating to content review and selection, identifying and completing key areas where content and evaluation questions are needed, analysis of evaluations and user feedback, and generating ideas for further developments and enhancements to the Universe. 

Editors

Kenneth R. DeVault, MD, FACG
Consultant: AstraZeneca, Takeda
Research Support: AstraZeneca, Addex
Education Support: AstraZeneca, Takeda, Janssen

David A. Johnson, MD, FACG
Research Grant: AstraZeneca, Takeda
Consultant: AstraZeneca, Takeda, Novartis, CRH Medical, Eisai, Xenoport

Philip O. Katz, MD, FACG
Honoraria for Lectures: Takeda
Consultant: Novartis, Takeda, Xenoport
Adjudicator: Eisai

Brooks D. Cash, MD, FACG
Consultant and In-kind Research Assistance: Salix Pharmaceuticals

David T. Rubin, MD, FACG
Consultant: Abbott, Centocor, Shire, Takeda, UCB, Warner Chilcott
Research Support: Abbott, Salix, Warner Chilcott
Scientific Advisory Committee: CCFA

Mitchell L. Shiffman, MD, FACG
Adivsory Board: Anadys, Bayer, Biolex, Bristol Myers Squibb, Celera Diagnostics, Conatus, Eschosense, Exalenz, Gilead, Human Genome Sciences, Merck, Novartis, Pfizer, Roche, Romark, Salix, Schering-Plough, Valeant, Vertex, Zymogenetics
Consultant: Exalenz, Roche
Data Safety Monitoring Board: Anadys
Grant Support: Biloex, Celera Diagnostics, Conatus, Exalenz, Gilead, Glaxo Smith Kline, Globeimmune, Human Genome Sciences, Idenix, Johnson/Johnson/Tibotec, Pharmacett, Roche, Romark, Schering-Plough, Valeant, Vertex, Wyeth, Zymogenetics
Speaker: Bayer, Bristol Myers Squibb, Roche, Schering-PloughStock Options: Exalenz